par
Gus Iversen, Editor in Chief | May 01, 2026
PharmaLogic Holdings Corp. has opened a new PET radiopharmaceutical manufacturing facility in Atlanta, expanding its production footprint in the southeastern United States.
The company, a Boca Raton, Florida-based contract development and manufacturing organization focused on radiopharmaceuticals, said the site is intended to increase regional access to diagnostic and therapeutic imaging agents while supporting ongoing research and development efforts.
“The opening of our Atlanta facility marks another critical step in our $250 million investment to address the deficit of radiopharmaceutical infrastructure in the U.S.,” said Etienne Montagut, president and CEO of PharmaLogic. “This state-of-the-art PET manufacturing facility will bring advanced radiopharmaceuticals to patients in the Southeast and surrounding areas, and will serve as a hub for supporting the development of next-generation radiopharmaceuticals.”
Ad Statistics
Times Displayed: 11501
Times Visited: 33 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
The Atlanta facility is equipped for PET radiopharmaceutical production and includes dedicated capacity for research activities. Its location is expected to improve delivery times for short-lived isotopes, which require rapid distribution to hospitals and imaging centers.
The site adds to a series of recent openings by the company in Cincinnati; New York; Salt Lake City; and Los Angeles. PharmaLogic said the expansion is part of a broader effort to scale domestic manufacturing infrastructure and strengthen its distribution network.
According to the company, its global platform spans more than 45 facilities across the United States, Puerto Rico, Canada and Norway, producing over 2.5 million doses annually. Its services include development, manufacturing and distribution of both clinical- and commercial-stage radiopharmaceuticals.
Radiopharmaceutical capacity has been an area of focus across the industry as demand grows for imaging and targeted therapies in oncology and other specialties, particularly those requiring time-sensitive logistics and specialized production environments.
